Linagliptin & Metformin Hydrochloride Tablets – Laglin M 2.5/500 Tablets

Laglin M 2.5/500 Tablets – Dual-Action Therapy for Enhanced Glycemic Control.

Laglin M 2.5/500 Tablets – The Dual combination of linagliptin & metformin hydrochloride tablets is designed to provide comprehensive glycemic management for patients with type 2 diabetes. Linagliptin, a DPP-4 inhibitor, prolongs the activity of incretin hormones, increasing insulin release and reducing glucagon secretion in a glucose-dependent manner. Metformin works by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. Together, these agents target both fasting and postprandial glucose levels effectively.

Key Benefits of Linagliptin & Metformin Hydrochloride Tablets – Laglin M 2.5/500 Tablets
✅Dual Action for Glycemic Control: Linagliptin (DPP-4 inhibitor) boosts incretin activity, enhancing insulin secretion and reducing glucagon levels, while Metformin suppresses hepatic glucose production and improves insulin sensitivity.
✅Convenient Combination Therapy: Combines two complementary agents in one tablet, simplifying treatment regimens and improving adherence.
✅Minimal Risk of Hypoglycemia and Weight Neutrality: Offers effective glycemic control without significant risk of hypoglycemia or weight gain, making it suitable for long-term use.

Recommended By Specialists:
👨‍⚕️Diabetologists: Specialized in diabetes care, to improve glycemic control, especially in patients with poor response to single drug therapy.
👨‍⚕️Endocrinologists: Primary prescribers for type 2 diabetes which is often recommended when monotherapy (either metformin or a DPP-4 inhibitor like linagliptin) is insufficient to control blood glucose levels, especially when diet and exercise alone are not enough.
👨‍⚕️General Physicians: For managing type 2 diabetes in patients who need oral combination therapy to effectively control blood sugar.

INDICATIONS:
✅Type 2 Diabetes Mellitus
✅Fasting and Postprandial Hyperglycemia
✅Overweight or High-Risk Patients